It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason. Most biotech companies fail, as their success often hinges on receiving regulatory approval for their products. It is an extremely high-risk sector to invest in. For every promising biotech company that successfully navigates clinical trials and generates multibagger returns, there are 99 others that either fail outright or struggle to deliver any gains at all. These stocks ...